Galera Therapeutics, Inc.
GRTX
|
$0.1833
-1.45%
-1.47%
800K
|
Health Technology
(0.0% 1d) (-21.6% 1m) (-93.2% 1y) (0.0% 2d) (-5.0% 3d) (24.3% 7d) (-77.23% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 9,970,085
http://www.galeratx.com
Sec Filling | Patents | 32 employees
Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The firm involves in the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. Its product candidate, GC4419, reduces severe oral mucositis in patients with head and neck cancer undergoing radiation therapy and also receiving cisplatin, a chemotherapy drug. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.
cancer education radiation therapy oral mucositis fibrosis msa treatment
add to watch list Paper trade email alert is off
Press-releases
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
Published: 2024-03-28 (Crawled : 11:00) - globenewswire.com
GRTX | $0.1833 -1.45% -1.47% 800K
|
Health Technology
|
| O: 2.67%
H: 17.39%
C: -11.17%
year financial results
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Published: 2023-11-14 (Crawled : 12:00) - globenewswire.com
GRTX | $0.1833 -1.45% -1.47% 800K
|
Health Technology
|
| O: 10.21%
H: 0.6%
C: -6.73%
financial results
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
Published: 2023-10-31 (Crawled : 11:00) - globenewswire.com
GRTX | $0.1833 -1.45% -1.47% 800K
|
Health Technology
|
| O: -55.07%
H: 12.64%
C: 2.32%
update meeting
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
Published: 2023-09-18 (Crawled : 11:00) - globenewswire.com
GRTX | $0.1833 -1.45% -1.47% 800K
|
Health Technology
|
| O: 6.95%
H: 0.0%
C: -5.45%
fda meeting avasopasem
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Published: 2023-09-05 (Crawled : 11:00) - globenewswire.com
GRTX | $0.1833 -1.45% -1.47% 800K
|
Health Technology
|
| O: 1.51%
H: 2.0%
C: 0.05%
conference global
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
Published: 2023-08-14 (Crawled : 11:00) - globenewswire.com
GRTX | $0.1833 -1.45% -1.47% 800K
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: -7.03%
financial results
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
Published: 2023-08-09 (Crawled : 21:00) - globenewswire.com
GRTX | $0.1833 -1.45% -1.47% 800K
|
Health Technology
|
| O: -82.81%
H: 6.1%
C: -6.49%
fda response avasopasem
Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim
Published: 2023-08-03 (Crawled : 21:00) - prnewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: -0.11%
H: 4.35%
C: 1.85%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: 0.0%
RCUS 4 | $14.59 -1.69% 0.0% 600K
|
Health Technology
|
| O: 0.11%
H: 1.42%
C: -0.16%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.43%
H: 0.0%
C: 0.0%
MRUS | $39.83 -1.58% -1.61% 800K
|
Health Technology
|
| O: -0.23%
H: 1.85%
C: 0.15%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.8%
H: 0.99%
C: -1.29%
GRTX | $0.1833 -1.45% -1.47% 800K
|
Health Technology
|
| O: 0.45%
H: 4.02%
C: 0.45%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -0.01%
H: 1.23%
C: -0.15%
AGEN | $5.3 6.64% 6.23% 1.5M
|
Health Technology
|
| O: 0.69%
H: 3.08%
C: 0.0%
companies expected pancreatic tumor endocrine growth market
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting
Published: 2023-06-05 (Crawled : 18:00) - globenewswire.com
GRTX | $0.1833 -1.45% -1.47% 800K
|
Health Technology
|
| O: -0.32%
H: 1.12%
C: -2.24%
disease kidney asco meeting trial
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer
Published: 2023-05-18 (Crawled : 12:00) - globenewswire.com
GRTX | $0.1833 -1.45% -1.47% 800K
|
Health Technology
|
| O: 1.85%
H: 0.27%
C: -9.06%
fda drug rucosopasem granted cancer pancreatic designation
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10